# A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

> **NCT00885365** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 324 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** tobramycin / Bramitob
- **DRUG:** tobramycin / TOBI

## Key facts

- **NCT ID:** NCT00885365
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-04
- **Final completion:** 2010-05
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885365, "A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00885365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*